- Home
- BKKT vs PBYI Comparison
BKKT vs PBYI Comparison
Compare BKKT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKKT | PBYI |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | 48 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.5M | 343.9M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | BKKT | PBYI |
|---|---|---|
| Price | $9.24 | $7.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $21.50 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 261.0K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $261.39 | N/A |
| P/E Ratio | ★ N/A | $12.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.87 | $2.75 |
| 52 Week High | $49.79 | $7.90 |
Technical Indicators
Market Signals| Indicator | BKKT | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 64.48 |
| Support Level | $8.86 | $5.75 |
| Resistance Level | $10.51 | N/A |
| Average True Range (ATR) | 0.60 | 0.33 |
| MACD | 0.30 | 0.11 |
| Stochastic Oscillator | 91.51 | 76.91 |
Price Performance
Historical ComparisonAbout BKKT Bakkt Holdings Inc.
Bakkt Inc builds digital financial infrastructure designed to support institutional participation in the digital asset economy. The company platform is built to accommodate various digital assets and offers its clients the flexibility to build a product that aligns with its vision and customers' needs. Its services include Bakkt Markets, Bakkt Agent, Bakkt Global.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.